glp-1 leaky gut Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use | Current Obesity Reports GLP-1 is released from the

Early trials suggest possible benefits for Parkinsons disease

In December 2025, the TRIUMPH-4 trial reported that retatrutide 12 mg achieved a remarkable 28.7% mean weight loss at 68 weeks in patients with obesity and knee osteoarthritis, with substantial pain relief as well ( [71] )

Laws vary by jurisdiction and individual circumstances

People who experience bloating on tirzepatide sometimes reduce their fluid intake to manage discomfort, which can compound the dehydration problem

IPCE Credit This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change

Good candidates typically have a BMI over 30, or a BMI of 27 or higher along with one or more weight-related health conditions such as type 2 diabetes, high blood pressure, or high cholesterol